Form 4 for PLRX PLIANT THERAPEUTICS, INC.
Accepted 2023-03-31 00:00:00 ET · period of report 2023-03-29 · accession 0001209191-23-021915 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-31 | 2023-03-29 | PLRX | Coulie Bernard | Pres, CEO, Dir | A - Grant | $0.00 | +68.7K | 310.1K | +28% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-29 | A | A | 68,749 | $0.00 | 310,092 | D | — | — | (F1) On July 28, 2022, the Reporting Person was granted 275,000 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On March 29, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 68,749 shares. (F2) Includes 1,231 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program. |